Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04195854 · ClinicalTrials.gov registry record
STARS-R Registry: Retrospective Analysis of Poly-4-hydroxybutyrate (P4HB) Scaffold Use
A clinical trial, sponsored by C. R. Bard.
- Completed
- Registry status
- 1,183
- Enrollment target
NCT04195854: Completed study, sponsored by C. R. Bard.
NCT04195854 is a clinical trial that has completed, run by C. R. Bard. The registered enrollment target is 1,183 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04195854 has completed, sponsored by C. R. Bard.
- COMPLETED
- Registry status
- 1,183 participants
- Enrollment target
Study Summary
This is a retrospective chart review performed at multiple clinics aimed at providing real-world evidence of the use and safety of the P4HB scaffold. Data on patient demographics, relevant medical history, product and procedure used, product safety, and outcome measures will be collected as available.
Primary Outcome
To obtain data from real-world utilization of P4HB scaffolds in order to evaluate how and why these products are being used and to assess the safety of these products
Interventions
- DEVICE P4HB product
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,183 participants |
| Start Date | 2019-12-17 |
| Est. Completion | 2022-01-31 |
What the finished NCT04195854 record still lists
NCT04195854 is an observational study that tracks outcomes without assigning an intervention. Its 1,183 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which P4HB product is the first listed.
NCT04195854 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04195854 about?
NCT04195854 is a clinical study titled "STARS-R Registry: Retrospective Analysis of Poly-4-hydroxybutyrate (P4HB) Scaffold Use". This is a retrospective chart review performed at multiple clinics aimed at providing real-world evidence of the use and safety of the P4HB scaffold. Data on patient demographics, relevant medical history, product and procedure used, product safety, and outcome measures will be collected as availabl...
What is the current status of trial NCT04195854?
This trial is currently completed. The enrollment target is 1,183 participants. The study started on 2019-12-17. Estimated completion is 2022-01-31.
What interventions are being tested in trial NCT04195854?
The interventions under investigation include: P4HB product (DEVICE).
Who is sponsoring clinical trial NCT04195854?
This trial is sponsored by C. R. Bard, which has 75 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07286058 · 1,182 participants · Phase 3
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
- NCT04293562 · 1,186 participants · Phase 3
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- NCT05580419 · 1,188 participants · NA
Impact of 4PCP on Practitioner and Patient Outcomes
- NCT06290869 · 1,188 participants · Phase 3
Tobacco Education and Lung Health Study (TEAL)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI